Pyrazolo[1,5-a]pyrimidine derivatives, their preparation methods and uses
By developing pyrazolo[1,5-a]pyrimidine derivatives as PI3Kα inhibitors, the problems of drug resistance and toxicity of existing PI3Kα inhibitors in cancer treatment have been solved, and effective treatment of cancers with dysregulated PI3Kα signaling pathways has been achieved.
Patent Information
- Application Number
- CN202210442580.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-04-25
- Publication Date
- 2026-05-26
- Estimated Expiration
- 2042-04-25
AI Technical Summary
Existing PI3Kα inhibitors exhibit drug resistance and lack specificity in cancer treatment, leading to intolerable toxicity and an inability to effectively inhibit cancers caused by dysregulation of the PI3Kα signaling pathway.
A pyrazolo[1,5-a]pyrimidine derivative and its tautomers, stereoisomers or pharmaceutically acceptable salts thereof have been developed as PI3Kα inhibitors for the treatment of cancers caused by dysregulation of the PI3Kα signaling pathway, such as breast cancer, lung cancer or rectal cancer.
This compound can effectively inhibit the PI3Kα signaling pathway, exhibiting high selectivity and novelty. It provides a new strategy for treating cancers caused by PI3Kα signaling pathway dysregulation and has promising application prospects.